Commercial Launch Marks a Key Step in Enhancing Early Detection of Acute Kidney Injury through Biomarker-Based Testing ...
New technology isolates extracellular vesicles from blood to enable earlier, non-invasive disease detection and personalized treatment strategies....
The partnership aims to deliver a non-invasive, hospital-compatible diagnostic using Aptamer’s Optimer binders and Neuro-Bio’s novel early-stage biomarker, with commercial rollout targeted within 12–18 months....
Unveiled at ESCMID Global Congress 2025, the new Hyperbaric Heating-based platform eliminates the need for extraction kits—delivering faster, simpler, and cost-effective molecular workflows across diverse research and diagnostic applications....
New results from the VERIFI study show Immunovia's test accurately detects 77% of early-stage cases and maintains strong specificity across diverse high-risk groups—strengthening commercial launch plans for Q3 2025....
With low false positives and broad detection capabilities, Volition’s Nu.Q® test could reshape the $20B liquid biopsy market, as the company advances licensing talks with major diagnostic players. ...
Collaboration aims to enhance pharmaceutical innovation and expand access to high-quality healthcare solutions worldwide. ...
The integrated clinical chemistry and immunoassay system enhances efficiency, streamlines lab workflows, and delivers accurate diagnostics in a compact design....
Court ruling dismisses claims against Co-Diagnostics, reinforcing the company’s commitment to transparency and innovation in molecular diagnostics....
The agreement aims to expand access to Geko™, a non-invasive device designed to reduce edema, prevent DVT, and improve recovery after orthopedic procedures....
